Kerala: SMA drug row backfires on CPI-M
The controversy over the supply of an Indian made drug to children suffering from Spinal Muscular Atrophy (SMA) has put the CPI-M on the backfoot, with questions emerging over the role of the previous LDF government in the procurement process. With the Assembly session set to resume on Monday, the issue is likely to figure prominently in the House. What was intended as a tactical move by the CPI-M to corner Health Minister K.
Muraleedharan by fielding three former women Health Ministers from the CPI-M now appears to have backfired, potentially providing the Minister with ammunition to counter…
Read the full report on Prokerala
Story file
How this page works. The Headline Update lists this report from Prokerala with a short summary and a link to the original. The original reporting belongs to the publisher. Spotted an error in our summary? Tell our corrections desk.
